Loading...

Brilliant Violet 605™ anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_BV605_072412
C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8a (clone 53-6.7) BV605™.
  • 53-6.7_BV605_072412
    C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8a (clone 53-6.7) BV605™.
See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
100743 125 µL $209
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100744 50 µg $273
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed
  2. Young JS, et al. 2018. Front Immunol. 9:1385. PubMed
  3. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  4. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  5. Schmid MC, et al. 2018. Nat Commun. 9:5379. PubMed
  6. Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
  7. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  8. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  9. Anderson CK et al. 2019. Cell Rep. 27(2):537-548 . PubMed
  10. Imbratta C, et al. 2019. Sci Rep. 9:6135. PubMed
  11. Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed
  12. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  13. Li Q, et al. 2019. Front Pharmacol. 10:786. PubMed
  14. Zhou AC, et al. 2019. J Immunol. 202:2482. PubMed
  15. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  16. Mathur AN, et al. 2019. Immunity. 50:655. PubMed
  17. van der Veeken J et al. 2019. Immunity. 50(5):1202-1217 . PubMed
  18. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  19. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  20. Grizotte–Lake M, et al. 2018. Immunity. 49:1103. PubMed
  21. Scharschmidt TC, et al. 2017. Cell Host Microbe. 1.199305556. PubMed
  22. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  23. Chauveau A, et al. 2020. Immunity. 52:794. PubMed
  24. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  25. Liu Y, et al. 2019. Sci Rep. 9:18970. PubMed
  26. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  27. Olguín JE, et al. 2018. J Cancer. 9:239. PubMed
  28. Xiao S, et al. 2020. Cell Reports. 32(2):107892. PubMed
  29. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  30. Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed
  31. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  32. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  33. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  34. Chen L, et al. 2020. J Exp Med. 217:00:00. PubMed
  35. Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed
  36. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  37. Tummers B, et al. 2020. Immunity. 52(6):994-1006.e8. PubMed
  38. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  39. Bilate AM, et al. 2020. Immunity. 53(5):1001-1014.e20. PubMed
  40. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  41. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  42. Yousif AS, et al. 2020. Immunity. 54(2):235-246.e5. PubMed
  43. Zhang S, et al. 2021. Cell. 184(8):2151-2166.e16. PubMed
  44. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  45. Shreeve N, et al. 2021. Immunity. 54(6):1231-1244.e4. PubMed
  46. Pritykin Y, et al. 2021. Molecular Cell. 81(11):2477-2493.e10. PubMed
  47. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  48. Giampazolias E, et al. 2021. Cell. . PubMed
  49. Dupraz L, et al. 2021. Cell Reports. 36(1):109332. PubMed
  50. Toubal A, et al. 2020. Nat Commun. 3755:11. PubMed
  51. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  52. Nato G, et al. 2021. Sci Rep. 11:651. PubMed
  53. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  54. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  55. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  56. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  57. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
  58. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  59. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  60. Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed
  61. Du P, et al. 2022. Front Pharmacol. 13:805508. PubMed
  62. Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
  63. Teng ZX, et al. 2022. J Inflamm Res. 15:3187. PubMed
  64. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  65. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  66. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  67. Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
  68. Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed
  69. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  70. Qiu F, et al. 2022. J Cancer. 13:2893. PubMed
  71. Wennerberg E, et al. 2022. Sci Transl Med. 14:eabe8195. PubMed
  72. Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed
  73. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  74. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  75. Kim E, et al. 2022. Immunity. 55:145. PubMed
  76. Ning J, et al. 2022. Cancer Immunol Immunother. 71:1863. PubMed
  77. Paik D, et al. 2022. Nature. 603:907. PubMed
  78. Merana GR, et al. 2022. Cell Rep. 39:110891. PubMed
  79. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  80. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  81. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  82. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  83. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  84. Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed
  85. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  86. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  87. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  88. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  89. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  90. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
RRID
AB_2561352 (BioLegend Cat. No. 100743)
AB_2562609 (BioLegend Cat. No. 100744)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org
Go To Top Version: 3    Revision Date: 01/21/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account